Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 77

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 2
Chunk 77
---
 approximately $230,000 of lower compensation costs associated with reduced
headcount and bonus accruals, as well as a $41,000 decline in stock-based compensation.

The
decrease in General and Administrative expenses of approximately $437,000 for the three months ended September 30, 2025, was primarily
driven by fluctuations across several categories. Supplies decreased by approximately $68,000, reflecting prior-year raw material purchases
with no comparable purchases in the current period. Clinical trial expenses decreased by approximately $97,000 compared to the prior year
period, primarily reflecting the recognition of a $218,000 R&D tax incentive for Australian R&D related to the trial, the timing
of trial-related activities, which were higher in the prior period due to the initiation of new study sites and related startup costs
and the closure of the India COVID 19 trial. Insurance
expense decreased by approximately $35,000, primarily due to lower medical insurance costs associated with reduced headcount. Utilities
and business-related taxes decreased by approximately $10,000 and $9,000, respectively, mainly due to timing and usage patterns. Additional
variances of approximately $6,614 in computer software and $23,000 across various other categories contributed to the overall change.
These variances largely reflect timing differences and routine operational adjustments during the period. 

The approximate $177,000 decrease in professional
fees for the three months ended September 30, 2025, was primarily driven by a $265,000 reduction in investor relations expenses, reflecting
the prior year engagement of an investor relations firm and our annual meeting, with no comparable activities in the current period and
an approximate $12,000 decrease in contract labor. This decrease was partially offset by approximately $79,000 in legal fees related to
additional patent filings and maintenance and $20,000 in tax, audit, and financial services.

Other  Income, Net

We recorded other income of $22,730 for the three
months ended September 30, 2025 compared to other income of $95,146 for the three months ended September 30, 2024. Other income in both
periods was primarily interest income.

Net Loss

As a result of the changes in expenses noted above,
our net loss decreased to $1,487,100 in the three months ended September 30, 2025 from $2,806,973 in the three months ended September
30, 2024.

Basic and diluted loss